Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing


About this study

The purpose of the MODULAR ATP Clinical Study is to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Patient who meets Class I, IIa, or IIb guideline ICD indications[i],[ii], or who has
an existing TV-ICD[iii] or S-ICD[iv]

- Patient who is deemed to be at risk for MVT based on at least ONE of the following:

- History of Non-Sustained MVT with LVEF ≤ 50%

- History of sustained VT/VF (secondary prevention) with LVEF ≤ 50% or significant
cardiac scar*

- History of syncope deemed to be arrhythmic in origin

- History of ischemic cardiomyopathy with LVEF ≤ 35%

- History of non-ischemic cardiomyopathy with LVEF ≤ 35% and significant scar*

- Patient who is willing and capable of providing informed consent (which is not to
include the use of a legally authorized representative (LAR) for documentation of
informed consent) and participating in all testing associated with this investigation
at an approved study site and at the intervals defined by this protocol

- Patient who is age 18 years or above, or of legal age to give informed consent
specific to state and national law

Exclusion Criteria:

- Patient with an ongoing complication due to Cardiac Implantable Electronic Device
(CIED) infection or CIED explant

- Transvenous lead remnants within the heart from a previously implanted CIED (Note:
transvenous lead remnants outside the heart (e.g., in the SVC) are allowed)

- Patient with a known LA thrombus

- Patient with a ventricular arrhythmia due to a reversible cause

- Patient indicated for implantation of a dual chamber pacemaker or cardiac
resynchronization therapy (CRT)

- Patient with another implanted medical device that could interfere with implant of the
leadless pacemaker, such as an implanted inferior vena cava filter or mechanical
tricuspid heart valve

- Patient requires rate-responsive pacing therapy

- Patient is entirely pacemaker-dependent (defined as escape rhythm ≤ 30 bpm)

- Patient with Acute Coronary Syndrome (i.e. Acute Myocardial Infarction, Unstable
Angina) within 40 days

- Inability to access femoral vein with a 21-French (inner diameter)/ 23.5-French outer
diameter) introducer sheath due to known anatomy condition, recent surgery, and/ or
other relevant condition

- Patient who has an active implanted electronic medical device intended for chronic use
concomitantly with the study system, such as a left ventricular assist device (LVAD).
Note that a temporary pacing wire is allowed.

- Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)

- Patient with a known cardiovascular anatomy that precludes implant in the right

- Patient with a known allergy to any system components

- Patient with a known or suspected intolerance to S-ICD conversion testing, based on
physician discretion

- Patient is not likely to have meaningful survival** for at least 12 months (documented
or per investigator's discretion)

- Patient is enrolled in any other concurrent study. Co-enrollment into other studies
such as observational studies/ registries needs prior written approval by BSC. Local
mandatory governmental registries are accepted for co-enrollment without approval by

- Patient who is a woman of childbearing potential who is known to be pregnant at the
time of study enrollment (method of assessment upon investigator's discretion)

[i]Al-Khatib, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the
American College of Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines and the Heart Rhythm Society. Circulation. (2018); 138:e272-e391.

[ii] 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and
the prevention of sudden cardiac death: The Task Force for the Management of Patients with
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society
of Cardiology (ESC). European Heart Journal (2015) 36, 2793-2867.

[iii] TV-ICD system is expected to be fully explanted during or prior to full Coordinated
System implant

[iv] Potential subjects with a Model 1010 S-ICD Pulse Generator are only eligible for
MODULAR ATP if they are getting upgraded to Model A209, A219 or future BSC S-ICD Pulse
Generator; Patients with an existing S-ICD PG subject to the electrical overstress field
action are only eligible for MODULAR ATP if they are getting a new BSC Model A209 or A219,
or future BSC S-ICD Pulse Generator

*Significant cardiac scar is defined as a scar involving at least one ventricular
myocardial segment (i.e., basal infero-septum) as identified in the official findings of a
cMRI, or nuclear viability study, or echo report by the interpreting radiologist/
cardiologist who is not affiliated with the study

**meaningful survival means that a patient has a reasonable quality of life and functional

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yongmei Cha, M.D.

Open for enrollment

Contact information:

CVRU Heart Rhythm Services Research Team

(507) 255-0774

More information


Publications are currently not available